Pharmacokinetics and predicted neutralization coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials

Yunda Huang, Logashvari Naidoo, Lily Zhang, Lindsay N. Carpp, Erika Rudnicki, April Randhawa, Pedro Gonzales, Adrian McDermott, Julie Ledgerwood, Margarita M. Gomez Lorenzo, David Burns, Allan DeCamp, Michal Juraska, John Mascola, Srilatha Edupuganti, Nyaradzo Mgodi, Myron Cohen, Larry Corey, Philip Andrew, Shelly Karuna, Peter B. Gilbert, Kathryn Mngadi, Erica Lazarus
doi: https://doi.org/10.1101/2020.09.02.20182881

Article Information

doi 
https://doi.org/10.1101/2020.09.02.20182881
History 
  • September 3, 2020.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

Author Information

  1. Yunda Huang1,2,3,*,
  2. Logashvari Naidoo4,
  3. Lily Zhang1,
  4. Lindsay N. Carpp1,
  5. Erika Rudnicki1,
  6. April Randhawa1,
  7. Pedro Gonzales5,
  8. Adrian McDermott6,
  9. Julie Ledgerwood6,
  10. Margarita M. Gomez Lorenzo7,
  11. David Burns7,
  12. Allan DeCamp1,2,
  13. Michal Juraska1,2,
  14. John Mascola6,
  15. Srilatha Edupuganti8,
  16. Nyaradzo Mgodi9,
  17. Myron Cohen10,
  18. Larry Corey1,11,
  19. Philip Andrew12,
  20. Shelly Karuna1,
  21. Peter B. Gilbert1,2,13,
  22. Kathryn Mngadi14 and
  23. Erica Lazarus15
  1. 1Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
  2. 2Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
  3. 3Department of Global Health, University of Washington, Seattle, Washington, United States of America
  4. 4HIV Prevention Research Unit, South African Medical Research Council, Durban, South Africa
  5. 5Asociacion Civil Impacta Salud y Educacion, Lima, Perú
  6. 6Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States of America
  7. 7Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States of America
  8. 8Division of Infectious Diseases, Department of Medicine, Emory University, Decatur, United States of America
  9. 9Clinical Trials Research Centre, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe
  10. 10Department of Medicine, Division of Infectious Diseases, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA; Institute for Global Health and Infectious Diseases, University of North Carolina, Chapel Hill, NC, United States of America
  11. 11Departments of Medicine and Laboratory Medicine, University of Washington, Seattle, Washington, United States of America
  12. 12Family Health International, Durham, NC
  13. 13Department of Biostatistics, University of Washington, Seattle, WA, United States of America
  14. 14Centre for the AIDS Programme of Research in South Africa, Durban, South Africa
  15. 15Perinatal HIV Research Unit (PHRU), Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, Gauteng, South Africa
  1. ↵*Correspondence: yunda{at}scharp.org
Back to top
Posted September 03, 2020.
Download PDF

Supplementary Material

Data/Code
Email
Pharmacokinetics and predicted neutralization coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials
Yunda Huang, Logashvari Naidoo, Lily Zhang, Lindsay N. Carpp, Erika Rudnicki, April Randhawa, Pedro Gonzales, Adrian McDermott, Julie Ledgerwood, Margarita M. Gomez Lorenzo, David Burns, Allan DeCamp, Michal Juraska, John Mascola, Srilatha Edupuganti, Nyaradzo Mgodi, Myron Cohen, Larry Corey, Philip Andrew, Shelly Karuna, Peter B. Gilbert, Kathryn Mngadi, Erica Lazarus
medRxiv 2020.09.02.20182881; doi: https://doi.org/10.1101/2020.09.02.20182881
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area